Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.05 (market cap $12.87B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.9× iShares JPMorgan USD Emerging Markets Bond ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EMB | VRTX | |
|---|---|---|
Market Cap | $12.87B | $127.55B |
Volume | 14,946,002 | 1,487,944 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $557.96 |
52-Week Low | $90.14 | $407.37 |
Typical Hold Time | 50 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $90.78, down 0.19% with a bearish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at oversold levels. Recent dividend declarations of $0.41-$0.44 per share provide income support, though key valuation ratios remain unavailable for analysis. Technical indicators suggest the stock is testing support levels near $90-$91.
The outlook remains cautious given the bearish technical momentum and limited fundamental data visibility. Income investors may find value in the dividend yield, but the lack of current financial metrics and bearish technical signals suggest near-term pressure. Market sentiment appears mixed with fixed income ETFs seeing inflows while emerging market bonds face AI-driven yield pressures.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
